A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan

Darul Sehat Hospital94 enrolled

Overview

This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Hepatocellular

Eligibility

Sex: ALLMin age: 27 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged between 27 to 80 years. * Diagnosed with hepatocellular carcinoma (HCC) within the last three months. * Diagnosis confirmed by relevant investigations (e.g., imaging, liver biopsy). * Able to provide informed consent. Exclusion Criteria: * Elevated alpha-fetoprotein levels due to tumors other than HCC. * Presence of secondary liver metastases from other primary sites. * Any significant comorbid conditions that could interfere with study assessments. * Pregnancy or breastfeeding.

Locations (1)

Darul Sehat Hospital

Karachi, Sindh, Pakistan

Outcomes

Primary Outcomes

Mean Alpha-Fetoprotein (AFP) Levels in HCC Patients

Time frame: Baseline measurement at time of diagnosis.

Secondary Outcomes

Correlation Between AFP Levels and Tumor Size

Time frame: At baseline (upon diagnosis).